MYD88 and lymphoplasmacytic lymphoma: For example, the discovery that an activating mutation of MYD88 is associated with most cases of lymphoplasmacytic lymphoma has made it possible to develop an allele-specific PCR method useful for better understanding this neoplasm, which often presents with clinical and histopathological characteristics which overlap with other forms, such as MZL [19,20].